AstraZeneca May Advance at Least 8 Drugs to Final Tests by 2015
This article is for subscribers only.
AstraZeneca Plc aims to advance at least eight medicines into late-stage tests within three years, one of its top research and development executives said today.
“We’ve set our R&D organization a goal of delivering eight to 11 Phase 3 projects,” Menelas N. Pangalos, executive vice president of the company’s Innovative Medicine Research Units, told reporters at a briefing in London.